Advertisement

Cell and Tissue Biology

, Volume 12, Issue 6, pp 460–467 | Cite as

The Cytotoxic Effect of Activated Recombinant Anti-Mullerian Hormone As a Basis for the Development of a New Drug

  • A. Ya. RakEmail author
  • A. V. Trofimov
  • N. V. Pigareva
  • A. S. Simbirtsev
  • A. M. Ischenko
Article
  • 4 Downloads

Abstract

In the present study, the antitumor activity of activated recombinant human anti-Mullerian hormone (rAMH) against the NBL-7 and OVCAR3 cell lines was investigated. It was shown that the hormone contained in highly purified preparations not only has the ability to bind to the recombinant type II receptor (MISRII), but also possesses a cytotoxic effect against cells expressing MISRII. The obtained data may underlie the basis for the development of the first domestic anticancer drug based on activated rAMH.

Keywords:

anti-Mullerian hormone AMH antitumor activity recombinant protein cytotoxicity 

Notes

REFERENCES

  1. 1.
    Cate, R.L., Donahoe, P.K., and MacLaughlin, D.T., Mullerian-inhibiting substance, in Peptide Growth Factors and Their Receptors, London: Springer, 1990, vol. 2, pp. 179–210.Google Scholar
  2. 2.
    Chang, H.L., Pieretti-Vanmarcke, R., Nicolaou, F., Li, X., Wei, X., MacLaughlin, D.T., and Donahoe, P.K., Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines, Gynecol. Oncol., 2011, vol. 120, pp. 128–134.CrossRefGoogle Scholar
  3. 3.
    Donahoe, P.K., Clarke, T., Teixeira, J., Maheswaran, S., and MacLaughlin, D.T., Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications, Mol. Cell. Endocrinol., 2003, vol. 211, pp. 37–42.CrossRefGoogle Scholar
  4. 4.
    Gukasova, N.V. and Severin, S.E., MIS protein: structure, regulation of expression and molecular mechanism of activity, Vopr. Biol. Med. Farmatsevt. Khim., 2005, vol. 4, pp. 3–9.Google Scholar
  5. 5.
    Hoshiya, Y., Gupta, V., Segev, D.L., Hoshiya, M., Carey, J.L., Sasur, L.M., Tran, T.T., Ha, T.U., and Maheswaran, S., Mullerian inhibiting substance induces NFkB signaling in breast and prostate cancer cells, Mol. Cell. Endocrinol., 2003, vol. 211, pp. 43–49.CrossRefGoogle Scholar
  6. 6.
    Jung, Y.S., Kim, H.J., Seo, S.K., Choi, Y.S., Nam, E.J., Kim, S.W., Han, H.D., Kim, J.W., and Kim, Y.T., Anti-proliferative and apoptotic activities of Müllerian inhibiting substance combined with calcitriol in ovarian cancer cell lines, Yonsei Med. J, 2016, vol. 57, pp. 33–40.CrossRefGoogle Scholar
  7. 7.
    Kim, J.H., MacLaughlin, D.T., and Donahoe, P.K., Müllerian inhibiting substance/anti-Müllerian hormone: a novel treatment for gynecologic tumors, Obstet. Gynecol. Sci., 2014, vol. 57, pp. 343–357.CrossRefGoogle Scholar
  8. 8.
    Lorenzo, H.K., Teixeira, J., Pahlavan, N., Laurich, V.M., Donahoe, P.K., and MacLaughlin, D.T., New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity, J. Chromatogr. B, 2002, vol. 766, pp. 89–98.CrossRefGoogle Scholar
  9. 9.
    MacLaughlin, D.T. and Donahoe, P.K., Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers, Future Oncol., 2010, vol. 6, pp. 391–405.CrossRefGoogle Scholar
  10. 10.
    Mahmood, T., and Yang, P.C., Western blot: technique, theory, and troubleshooting, N. Am. J. Med. Sci., 2012, vol. 4, p. 429.CrossRefGoogle Scholar
  11. 11.
    Masiakos, P.T., MacLaughlin, D.T., Maheswaran, S., Teixeira, J., Fuller, A.F., Shah, P.C., Kenneally, M.K., Dombkowski, D.M., Ha, T.U., Preffer, F.I., and Donahoe, P.K., Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS, Clin. Cancer Res., 1999, vol. 5, no. 11, pp. 3488–3499.Google Scholar
  12. 12.
    Pankhurst, M.W., Leathart, B.L.A., Batchelor, N.J., and McLennan, I.S., The anti-müllerian hormone precursor (proAMH) is not converted to the receptor-competent form (AMHN, C) in the circulating blood of mice, Endocrinology, 2016, vol. 157, pp. 1622–1629.CrossRefGoogle Scholar
  13. 13.
    Ragin, R.C., Donahoe, P.K., Kenneally, M.K., Ahmad, M.F., and MacLaughlin, D.T., Human Müllerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects, Protein Express. Purif., 1992, vol. 3, pp. 236–245.CrossRefGoogle Scholar
  14. 14.
    Rak, A.Ia., Trofimov, A.V., Pigareva, N.V., Simbirtsev, A.S., and Ishchenko, A.M., Monoclonal antibodies against the human anti-mullerian hormone receptor type II as a new tool for the diagnosis and therapy of cancer, Tsitokiny Vospalenie, 2017a, vol. 16, no. 3, pp. 58–61.Google Scholar
  15. 15.
    Rak, A.Ia., Trofimov, A.V., Protasov, E.A., Simbirtsev, A.S., and Ishchenko, A.M., Comparison studies of the properties of activated recombinant human anti-mullerian hormone, Ross. Immunol. Zh., 2017b, vol. 11, no. 20 4, pp. 755–757.Google Scholar
  16. 16.
    Teixeira, J., Maheswaran, S., and Donahoe, P.K., Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications, Endocr. Rev., 2001, vol. 22, pp. 657–674.Google Scholar
  17. 17.
    Ten Dijke, P., Fu, J., Schaap, P., and Roelen, B.A., Signal transduction of bone morphogenetic proteins in osteoblast differentiation, J. Bone Joint Surg., 2003, vol. 85, pp. 34–38.CrossRefGoogle Scholar
  18. 18.
    Walker, J.M., Gradient SDS polyacrylamide gel electrophoresis of proteins, in Basic Protein and Peptide Protocols, New York: Springer, 1994, pp. 35–38.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2018

Authors and Affiliations

  • A. Ya. Rak
    • 1
    • 2
    Email author
  • A. V. Trofimov
    • 1
  • N. V. Pigareva
    • 1
  • A. S. Simbirtsev
    • 1
  • A. M. Ischenko
    • 1
  1. 1.State Research Institute of Highly Pure BiopreparationsSt. PetersburgRussia
  2. 2.St. Petersburg State UniversitySt. PetersburgRussia

Personalised recommendations